AstraZeneca pulls women's cancer drug over PBS pricing
AstraZeneca is withdrawing Zoladex from the Australian market, leaving approximately 8,000 women who rely on the monthly injection to treat breast cancer, endometriosis and other conditions in uncertainty. The pharmaceutical company claims the price paid through the PBS is no longer commercially viable, though it has committed to continue supplying the drug free for patients with no alternative treatment options while negotiations continue for a stronger three-monthly injection. The withdrawal highlights growing tensions between pharmaceutical companies demanding higher prices and the…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.